Regulator of G protein signaling 3 protects against cardiac hypertrophy in mice

Journal of Cellular Biochemistry

Volumn 115, Issue 5, 2014, Pages 977-986

  Liu, Yu ^a   Huang, He ^a   Zhang, Yan ^a   Zhu, Xue Yong ^a   Zhang, Rui ^a   Guan, Li Hua ^a   Tang, Qizhu ^a   Jiang, Hong ^a   Huang, Congxin ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

ERK1 2; HYPERTROPHY; RGS3; SIGNAL TRANSDUCTION

Indexed keywords

ANGIOTENSIN II; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REGULATOR OF G PROTEIN SIGNALING 3; RGS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SURGERY; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ERK1/2; HYPERTROPHY; RGS3; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RGS PROTEINS;

EID: 84895551950     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24741     Document Type: Article

References (28)

1. Anger T, Grebe N, Osinski D, Stelzer N, Carson W, Daniel WG, Hoeher M, Garlichs CD,. 2008. Role of endogenous RGS proteins on endothelial ERK 1/2 activation. Exp Mol Pathol 85: 165-173.
2. Belmonte SL, Blaxall BC,. 2011. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res 109: 309-319.
3. Berk BC, Fujiwara K, Lehoux S,. 2007. ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568-575.
4. Bian ZY, Huang H, Jiang H, Shen DF, Yan L, Zhu LH, Wang L, Cao F, Liu C, Tang QZ, Li H,. 2010. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Hypertension 55: 257-263.
5. Chakir K, Daya SK, Aiba T, Tunin RS, Dimaano VL, Abraham TP, Jaques-Robinson KM, Lai EW, Pacak K, Zhu WZ, Xiao RP, Tomaselli GF, Kass DA,. 2009. Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation 119: 1231-1240.
6. Chakir K, Depry C, Dimaano VL, Zhu WZ, Vanderheyden M, Bartunek J, Abraham TP, Tomaselli GF, Liu SB, Xiang YK, Zhang M, Takimoto E, Dulin N, Xiao RP, Zhang J, Kass DA,. 2011. Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci Transl Med 3: 100ra88.
7. Cho H, Harrison K, Schwartz O, Kehrl JH,. 2003. The aorta and heart differentially express RGS (regulators of G-protein signalling) proteins that selectively regulate sphingosine 1-phosphate, angiotensin II and endothelin-1 signalling. Biochem J 371: 973-980.
8. Dorn GW II, Force T,. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115: 527-537.
9. Heineke J, Molkentin JD,. 2006. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell B0iol 7: 589-600.
10. Huang H, Tang QZ, Wang AB, Chen M, Yan L, Liu C, Jiang H, Yang Q, Bian ZY, Bai X, Zhu LH, Wang L, Li H,. 2010. Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 56: 232-239.
11. Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu Y, Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC, Li H,. 2013. Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 61: 1193-1202.
12. Leask A,. 2010. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106: 1675-1680.
13. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z, Bai X, Zhou H, Jiang H, Heximer SP, Qin M, Huang H, Liu PP, Huang C,. 2010. Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci USA 107: 13818-13823.
14. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, Liu DP, Liang CC,. 2007. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115: 1885-1894.
15. Lorell BH, Carabello BA,. 2000. Left ventricular hypertrophy: Pathogenesis, detection, and prognosis. Circulation 102: 470-479.
16. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ,. 1998. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 95: 13893-13898.
17. Minamino T, Yujiri T, Terada N, Taffet GE, Michael LH, Johnson GL, Schneider MD,. 2002. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci USA 99: 3866-3871.
18. Nishiura H, Nonaka H, Revollo IS, Semba U, Li Y, Ota Y, Irie A, Harada K, Kehrl JH, Yamamoto T,. 2009. Pro- and anti-apoptotic dual functions of the C5a receptor: involvement of regulator of G protein signaling 3 and extracellular signal-regulated kinase. Lab Invest 89: 676-694.
19. Nunn C, Zou MX, Sobiesiak AJ, Roy AA, Kirshenbaum LA, Chidiac P,. 2010. RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell Signal 22: 1231-1239.
20. Pandya K, Kim HS, Smithies O,. 2006. Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci USA 103: 16864-16869.
21. Rose BA, Force T, Wang Y,. 2010. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90: 1507-1546.
22. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, Mendelsohn ME, Kass DA,. 2009. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119: 408-420.
23. Tokudome T, Kishimoto I, Horio T, Arai Y, Schwenke DO, Hino J, Okano I, Kawano Y, Kohno M, Miyazato M, Nakao K, Kangawa K,. 2008. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 117: 2329-2339.
24. Wettschureck N, Rütten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S,. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7: 1236-1240.
25. Wieland T, Lutz S, Chidiac P,. 2007. Regulators of G protein signalling: A spotlight on emerging functions in the cardiovascular system. Curr Opin Pharmacol 7: 201-207.
26. Yau DM, Sethakorn N, Taurin S, Kregel S, Sandbo N, Camoretti-Mercado B, Sperling AI, Dulin NO,. 2008. Regulation of Smad-mediated gene transcription by RGS3. Mol Pharmacol 73: 1356-1361.
27. Zhang P, Mende U,. 2011. Regulators of G-protein signaling in the heart and their potential as therapeutic targets. Circ Res 109: 320-333.
28. Zhang S, Watson N, Zahner J, Rottman JN, Blumer KJ, Muslin AJ,. 1998. RGS3 and RGS4 are GTPase activating proteins in the heart. J Mol Cell Cardiol 30: 269-276.